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Nitrogen-containing heterocyclic compounds are the 
basis of many natural and synthetic biologically active 
substances.1 More than two-thirds of the known drugs used 
in clinical practice contain heterocyclic and, above all, 
nitrogen-containing fragments within their structure. Over 
the past decades, the chemistry of aza-heterocycles has 
received considerable attention due to the wide spectrum of 
their biological activity and numerous therapeutic 
applications in medicine. 
Of nitrogenous heterocycles, azoloazines containing 
fragments similar to the natural heterocycles purines and 
pyrimidines are currently of great practical importance. 
Thus, non-natural nucleosides abacavir, famciclovir, 
remdesivir are known, which are the products of structural 
modifications of all the components of the nucleotide 
exhibiting excellent indicators of antiviral action (Fig. 1).2–4 
In addition to the generally accepted nucleoside forms, 
the azoloazines themselves are relevant in the search for 
means of combating diseases on a global scale. Nitroazolo-
[5,1-c][1,2,4]triazines and nitroazolo[1,5-a]pyrimidines, a 
new family of antiviral compounds has been found.5 The 
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Figure 1. Azoloazine-based antiviral drugs. 
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medication Triazavirin (2-methylsulfanyl-6-nitro[1,2,4]-
triazolo[5,1-c][1,2,4]triazin-7-one sodium salt dihydrate) 
showed a broad spectrum of antiviral action and high 
efficacy. The medication protects against infection caused 
by influenza viruses,6–9 ARVI,10 tick-borne encepha-
litis.11,12 Triazavirin has been shown to be effective in 
treating patients with moderate COVID-19.13,14 Antiviral 
medication 5-methyl-6-nitro-7-oxo-4,7-dihydro[1,2,4]tri-
azolo[1,5-a]pyrimidine L-arginine salt monohydrate is at 
the stage of clinical trials.15,16 
At the same time, this is not the only method of 
constructing the important heterocyclic structures with 
relevant biological activity. Thus, numerous compounds 
containing benzimidazole scaffold which are isosteres of 
the nitrogenous bases of nucleic acids are known.17 Some 
of the most important drugs containing the benzimidazole 
structural element are shown in Figure 2. 
Currently, numerous compounds containing the 
benzimidazole moiety are known to exhibit various types 
of biological activity, including analgesic,18 antibacterial,19 
anticancer,20,21 antifungal,22 antiHIV,23 anti-inflammatory,24 
antimalarial,25 antimicrobial,26 antioxidant activity,27 as 
well as anti-tuberculosis28 and varied antiviral activities.29 
Thus, the creation of pharmacologically sound benz-
imidazole derivatives is an important task that requires 
complex synthetic approaches. 
Among the methods for the structural modification of 
benzimidazole scaffolds, the approach consisting in the 
creation of polycyclic condensed analogs with the 
participation of five- and six-membered structures is of 
particular interest and independent significance. Of the 
large number of polycyclic derivatives of benzimidazoles, 
pyrimido[1,2-a]benzimidazoles are of significant interest, 
having structural similarity both with benzimidazoles and 
with various azolo[1,5-a]pyrimidines which have also 
proven themselves as structures with relevant biological 
properties, including antiviral,5 antibacterial,30 anti-
septic,31,32 anticancer,33 and anti-glycation34 effects. In 
addition, annulated benzimidazoles with a conjugated 
planar structure exhibit relevant photophysical properties 
and find application in optoelectronics as phosphors and 
fluorescent dyes in textile and polymer materials.35 
Besides, pyrimido[1,2-a]benzimidazoles are of interest 
from the aspect of further modifications in the creation of 
macrocyclic derivatives, including, in particular, 
purinobenzimidazoles which are not described in the 
literature. 
This review examines and discusses the data on the main 
methods of construction and the possibilities of practical 
application of pyrimido[1,2-a]benzimidazole derivatives 
published in the past 10 years. The increased interest in 
such heterocyclic systems is due to the promise of the 
emergence of unique properties (biological active, 
photophysical, structural, etc.) because of the practical 
significance of the benzimidazole and azolo[1,5-a]-
pyrimidine scaffolds contained in pyrimido[1,2-a]-
benzimidazoles. 
To obtain the target heterocyclic systems of this type, 
two main synthetic strategies are currently actively used: 
the reaction of aminobenzimidazoles with bifunctional 
synthetic equivalents, and the construction of a pyrimido- 
benzimidazole structure by the method of multicomponent 
reactions. 
The reaction of aminobenzimidazoles 
with bifunctional synthetic equivalents 
One of the approaches to the construction of pyrimido-
[1,2-a]benzimidazoles and related polycyclic derivatives is 
based on the annulation of substituted benzimidazoles with 
bifunctional synthetic equivalents, the nature of which 
determines the reaction conditions. The most common and 
widely used example of bifunctional synthetic equivalents 
are derivatives of unsaturated carbonyl compounds. 
A team of authors from Egypt described the synthesis of 
pyrimidobenzimidazole derivative 3 containing a pyrazole 
substituent at position 2 (Scheme 1). It was demonstrated 
that the reaction of 2-aminobenzimidazole (1a) with the 
unsaturated ketone derivative 2 in EtOH under the 
conditions of basic catalysis leads to the target compound 
in good yield (71%).36 Another close illustration of the 
reaction of 2-aminobenzimidazoles with α,β-unsaturated 
carbonyl compounds 4 is the preparation of pyrimido[1,2-a]-
benzimidazoles 5a–t using a highly active reusable catalyst 
based on heterogeneous layered double hydroxides on a 
polyacrylic support (PAA-g-LDH) (Scheme 1, Table 1).37 
Carrying out the reaction without a solvent made it possible 
to obtain the final products 5a–t in more than 85% yields. 
Later publications report reactions with ethyl 
3-cinnamoyl-5-methyl-1-phenyl-1H-pyrazoles 6a,b and 
8a–d in EtOH with AcOH as a catalyst.38,39 However, in 
contrast to the above approach, in these reactions, a 
pyrazole substituent is introduced at position 4 of the 
benzimidazo[1,2-a]pyrimidine system with the formation 
of products 7a,b and 9a–d (Scheme 1). 
Photochemical condensation of 2-aminobenzimidazole 
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resulting in 96% yield of product 11. These examples 
indicate the importance of selection of conditions in the 
construction of the pyrimidobenzimidazole molecular 
structure. 
In 2014, Gao et al. developed an approach to the 
synthesis of the tracer for positron emission tomography 
T808 (18) and the corresponding mesylate precursor T808P 
(19) which are necessary for the detection of Alzheimer's 
disease (Scheme 3). The developed method included 
interaction of 2-aminobenzimidazole (1a) with 4-ethoxy-
butan-2-one (12). Subsequent hydrolysis of the 
trichloromethyl group in compound 13 leads to the 
formation of 2-hydroxypyrimido[1,2-a]benzimidazole (14), 
bromodeoxygenation of which and further nucleophilic 
substitution with 2-(piperidin-4 yl)ethanol (16) leads to the 
formation of adduct 17. Treatment of the latter with 
N,N-diethyltrifluorosulfamine and methanesulfonyl chloride 
leads to reference standard 18 in 51% yield and mesylate 
19 in 75% yield. A number of patent studies are devoted to 
the synthesis and elucidation of the properties of 









5a 4-i-PrC6H4 H 20 92 
5b 3-MeOC6H4 H 22 89 
5c 4-ClC6H4 H 22 90 
5d 4-MeC6H4 H 28 91 
5e 4-FC6H4 H 24 90 
5f 3,4,5-(MeO)3C6H2 H 29 91 
5g 4-EtOC6H4 H 20 92 
5h 3-O2NC6H4 H 25 85 
5i 3-BrC6H4 H 29 89 
5j 3-MeC6H4 3-OMe 28 91 
5k 2-MeC6H4 3-Me 24 91 
5l 3-FC6H4 4-Me 28 89 
5m 4-MeC6H4 4-Me 23 90 
5n 2-FC6H4 4-Br 29 91 
5o 4-i-PrC6H4 4-Me 22 92 
5p 3,4,5-(MeO)3C6H2 4-Me 25 89 
5q 4-BrC6H4 4-Me 29 88 
5r 2-ClC6H4 4-F 26 87 
5s 4-FC6H4 4-F 25 89 
5t 3-MeC6H4 4-Br 27 87 


















1(2H)-one (10) in the presence of KOH and DMF40 is 
demonstrated in Scheme 2. It was found that 312 nm is the 
most suitable wavelength for the reaction within 2 h 
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β-Enamine derivatives of ketones are important 
representatives of unsaturated carbonyl compounds for 
the construction of the pyrimidobenzimidazole system. 
Egyptian authors report the use of enaminonitriles 20 and 
22 in regioselective synthesis of pyrimidobenzimidazole 
derivatives 21, 23. The use of pyridine as a solvent allows 
the target products to be obtained in good yields (Scheme 4).45 
Brazilian scientists described the cyclocondensation 
reaction of β-enamino diketone 24 and 2-amino-
benzimidazole (1a) resulting in the formation of a 
glyoxylic derivative of pyrimido[1,2-a]benzimidazole 25.46 
The reaction is characterized by a good yield of the 
product. The obtained glyoxylate 25 is converted into 
pyrazinones and quinoxalinones 26a–e by the action of a 
number of 1,2-diamines (Scheme 5). 
Also presented are the results on the preparation of 
pyrimido[1,2-a]benzimidazoles 28, 30 containing thio-
phene and thieno[2,3-b]pyridinone fragments employing 
enaminones 27, 29 (Scheme 6).47,48 Interest in thiophene-
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great potential of these reagents as building blocks in the 
creation of pyrimidobenzimidazole scaffold. 
The use of α,β-unsaturated aldehydes to construct the 
pyrimidobenzimidazole scaffold was illustrated by Cho et 
al. The research team showed that β-bromo-α,β-unsaturated 
aldehydes 33a–j react with 2-aminobenzimidazole (1a) to 
form pyrimido[1,2-a]benzimidazoles 34a–j (Scheme 8).50 
Optimization of the synthesis conditions (Table 2) showed 
representation of this important structural fragment in 
biologically active compounds such as vitamin H, 
xanthopappin A, etc. 
Another variation of the reaction of compound 1a with 
β-enamines was demonstrated by Egyptian scientists using 
pyridazine derivative 31 as an example. The process takes 
place upon heating under reflux in pyridine to form 
pyrimidobenzimidazole 32 containing the pyridazine 
fragment which is relevant in medicinal chemistry (drugs 
hydralazine, dihydralazine) (Scheme 7).49 The approaches 
presented in this work using enamino ketones indicate the 
Scheme 6 
Entry Base Additive Solvent Yield, % 
1 K2CO3   DMF 42 
2 –   DMF 8 
3 K2CO3   DMF 45 
4 Cs2CO3   DMF 28 
5 NaOt-Bu   DMF 31 
6 K3PO4   DMF 37 
7 Et3N   DMF 50 
8 Et3N MgSO4 DMF 63 
9 Et3N MS 4 Å DMF 49 
10 – MgSO4 DMF 30 
11 Et3N MgSO4 DMSO 43 
12 Et3N MgSO4 1,4-Dioxane 0 
13 Et3N MgSO4 DMF 62 
14 Et3N MgSO4 DMF 43 
Scheme 8 
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that the use of DMF as a solvent under microwave 
irradiation in the presence of Et3N and MgSO4 is optimal. 
The developed approach represents a novel and efficient 
method for the synthesis of the hybrid structure of 
pyrimidobenzimidazoles from readily available β-bromo-
α,β-unsaturated aldehydes. 
Chromene aldehydes 35a–f were also successfully used 
in the synthesis of a number of condensed pentacyclic 
chromeno[3',2':5,6]pyrimido[1,2-a]benzimidazoles 36a–f 
(Scheme 9).51 According to the authors of the publication, 
the reaction was carried out under the conditions of 
sonochemical activation which resulted in product high 
yields (up to 88%) and also made it possible to 
significantly reduce the reaction time to 10 min. Due to the 
limited solubility of compounds 36a–f, for unambiguous 
determination of the structure by NMR, the methylation of 
compound 36a was carried out with the formation of 
N-methyl derivative 37a the structure of which was 
established on the basis of 2D NMR spectra. In addition, 
the reaction of derivatives 36a–f with thiocarboxylic acids 
was investigated and a mechanism for the formation of the 
products 38a–f was proposed. The author's interpretation of 
the formation of thiazolinones 38 involves the reaction of 
thioglycolate with the C-7 atom and the subsequent 
opening of the pyrimidine fragment. A significant 
advantage of the described approach is that in all reactions 
the chromone fragment of the molecule remains intact 
since the opening of the pyran ring is a limiting factor in 
many reactions with the participation of chromones. 
The instability of the chromone fragment is convin-
cingly presented in a publication from 2016. Thus, the 
reaction of chromonecarbonitrile 39 with 2-amino-
benzimidazole (1a) proceeds via the γ-opening of the 
pyrone ring followed by cycloaddition to the nitrile group 
and the formation of the pyrimidobenzimidazole structure 
40. Condensation was successfully carried out by heating 
in EtOH under reflux for 30 min with a product yield of 
74% (Scheme 10).52 
Scheme 9 Scheme 10 
Scheme 11 
In addition, a method was developed for the construction 
of condensed derivatives of pyrimido[1,2-a]benzimidazoles 
42a–r by cyclocondensation of 2-aminobenzimidazole (1a) 
with isoflavones 41a–r in MeOH in the presence of 3 equiv 
of MeONa (Scheme 11).53 This process is also 
accompanied by opening of the pyran ring followed by 
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cyclocondensation. The use of the developed synthetic 
strategy makes it possible to access pyrimido[1,2-a]-
benzimidazole derivatives 42a–r in high yields. 
Another example of the construction of the pyrimido-
benzimidazole system by condensation of aminobenz-
imidazole with unsaturated carbonyl compounds was 
demonstrated in a study the authors of which synthesized 
a series of 4-arylpyrimido[1,2-a]benzimidazoles 44a–d by 
cyclization of methyl cinnamates 43a–d with 2-amino-
benzimidazole (1a) in DMF in the presence of K2CO3 
(Scheme 12).54 The research team points to the 
regioselectivity of the process and postulates the formation 
of only 4-substituted pyrimidobenzimidazoles. 
Scheme 12 
Pyrimido[1,2-a]benzimidazolone 46 thus obtained was 
subsequently used to obtain a number of new 2-amino- and 
2-mercaptopyrimido[1,2-a]benzimidazoles 47, 48a,b 
(Scheme 13).55 In addition, compounds 47, 48 are relevant 
as participants in further functional transformations. 
Thus, due to the wide variety of components for 
condensation with the participation of 2-aminobenz-
imidazole, as well as the existence of effective catalytic 
systems, the creation of pyrimidobenzimidazoles based on 
α,β-unsaturated carbonyl compounds can be considered an 
effective approach. 
Mono- and dicarbonyl compounds together with their 
derivatives are important substrates for the formation of a 
pyrimidine fragment in the structure of condensed 
pyrimidobenzimidazoles. Fang et al. developed an 
efficient, not using metal catalysts method for the synthesis 
of benzimidazo[1,2-a]quinazoline derivatives 51a–i, 52a–c 
involving the step of ipso substitution of halogen in 
arylcarbonyl compounds 49a–i, 50a–c (Scheme 14).56 
Thus, derivatives of 2-fluoro-, 2-chloro-, 2-bromo-, and 
2-nitro-substituted arylaldehydes 49a–i and ketones 50a–c 
are very reactive in this kind of transformations, which 
allows the process to be carried out with yields of target 
products of more than 63%. Detailed studies have been 
carried out to optimize the reaction conditions. It was found 
that the best conditions for the process is to carry out the 
reaction in DMF in the presence of K2CO3 at 135°C. 
A group of Indian researchers proposed a three-step 
synthesis of condensed acridines 55a–k containing a 
pyrimidobenzimidazole structural fragment.57 At the first 
step, the synthesis of cyclohexanone derivative 53 from 
(2-amino-5-chlorophenyl)(phenyl)methanone (52) and 














a R1 =H (97%), b R1 = CF3 (68%), c R
1 = 3-Br (71%)
d R1 = 4-Br (76%), e R1 = 4-OMe (91%), f R1 = 6-F (92%)
g R1 = 5-Cl (63%), h R1 = 5-F (80%), i R1 = 5-OMe (96%)
O
R2








X = F, Cl, Br, NO2
K2CO3
DMF
Unsaturated carbonyl compounds are not limited to 
derivatives containing an ethylene moiety. A nontrivial 
method for constructing the pyrimidobenzimidazole 
fragment was proposed by researchers from France. They 
developed a simple and convenient method for the 
regioselective synthesis of fluorinated pyrimido[1,2-a]-
benzimidazole 46 by condensation of ethyl 4,4,4-tri-










44 a R = H (47%), b R = 2-F (45%),
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H2SO4 at 150°C for 6 h is carried out. The second step is 
the aldol-crotonic condensation of tetrahydroacridine 53 
with aromatic aldehydes, the products of which, α,β-un-
saturated acridones 54a–k, are reacted with 2-amino-
benzimidazole (1a) under the conditions of catalysis by 
KOH. This synthesis route allowed the researchers to 
obtain 8-aryl-2-chloro-16-phenyl-6,7-dihydrobenzimidazo-
[1',2':1,2]pyrimido[4,5-a]acridines 55a–k in 82–95% yields 
in the last step (Scheme 15). 
The use of carboxylic acid derivatives in the synthesis of 
pyrimidobenzimidazoles is illustrated.58,59 Gnanasekaran et 
al. have developed a method for the preparation of a series 
of benzimidazo[2,1-b]quinazolin-12(6H)-ones and pyrido-
[2',3':4,5]pyrimido[1,2-a]benzimidazol-5(11H)-ones 57a–h 
and 57'a–h via the reaction of 2-aminobenzimidazoles 1a,b 
with 2-haloaroyl chlorides 56a–h (Scheme 16).58 Thus, the 
treatment of 2-aminobenzimidazoles 1a,b with acid chloride 
56a–h in the presence of NaHCO3 in DMF at –10°С leads to 
acylation of the nitrogen atom of the imidazole ring. Upon 
subsequent heating of the reaction mixture to 75°C, an 
intramolecular SNAr process occurs accompanied by the 
formation of the pyrimidine ring. The yields of the reaction 
products are 76–98%. In addition, it was found that under 
the conditions of the acylation reaction of the obtained 
compounds, the formation of only 6-acetyl isomers 58a–e 
is observed. 
Galeterone derivatives containing the pyrimido-
benzimidazole fragment were successfully synthesized 
by the reaction of 2-aminobenzimidazoles 1a–c with 
16-dehydropregnenolone acetate (59). The target 
galeterone derivatives were obtained in good yields by 
heating under reflux in dry MeCN in the presence of 
p-TsOH (Scheme 17).60 Under these conditions, in addition 
to the predominant aromatic products 60a–c, 60'c, D-homo-
ketones 61a–c, 61'c were obtained which were formed as 
autoxidation products. In addition, from the mixture of 
derivatives 60c, 60'c and 61c, 61'c, the regioisomers were 
isolated as individual products. Compound 60''a was 
obtained in 42% yield by lowering the reaction temperature 
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An earlier publication also investigated the reaction of 
2-aminobenzimidazole (1a) with 16-dehydropregnenolone 
acetate (59). It was found that the reaction under basic 
catalysis conditions also proceeds with the formation of 
two derivatives 60a and 61a (Scheme 18).61 
 
Scheme 18 
A demonstration of the use of 1,3-dicarbonyl com-
pounds in the construction of the pyrimidobenzimidazole 
ring is presented in a publication from 2019. Researchers 
developed a simple and effective method for the synthesis 
of 2-polyfluoroalkylbenzimidazo[1,2-a]pyrimidine-4-carb-
aldehyde derivatives 63a,b with yields of up to 86% 
starting from 3-(polyfluoroacetyl)pyruvaldehyde dimethyl 
acetal 62a,b and 2-aminobenzimidazole (1a) (Scheme 19).62 
As the authors of the study note, the introduction of 
fluorinated substituents into the pyrimidobenzimidazole 
molecule is an effective method for changing the physical 
and chemical properties, as well as the biological activity 
of this class of compounds. The choice of reaction 
conditions has a decisive influence on the direction of the 
reaction. Thus, carrying out the reaction in MeCN in the 
presence of 3 equiv of (EtO)3B is characterized by high 
regioselectivity (98%) in favor of 2-fluoroalkyl-substituted 
acetals of pyrimido[1,2-a]benzimidazole-4-carbaldehydes 
63a,b. When trifluoroethanol is used without the presence 
of a Lewis acid, 4-fluoroalkyl derivatives 64a,b are 
formed. 
Scheme 19 
Kong et al. successfully synthesized a number of 
pyrimido[1,2-a]benzimidazole derivatives 66a–l via a 
chemoselective reaction of 2-aminobenzimidazoles 1 with 
3-ethoxycyclobutanones 65 under the conditions of 
catalysis by Lewis acid BF3·Et2O. The researchers found 
that when using monohalogenated 2-aminobenzimidazoles 
1, the formation of regioisomeric products is observed 
(similar to Scheme 19, according to 1H NMR spectro-
scopy), whereas in the case of unsubstituted and 5-methyl-
Scheme 20 
Scheme 21 
aminobenzimidazoles, the process proceeds regio-
selectively. In addition, it was noted that the developed 
approach can be easily scaled without decrease of the yield 
of the target products (Scheme 20).63 
The above approach to the construction of the 
pyrimidobenzimidazole structure using cyclic ketones is 
not the only example of the use of this kind of carbonyl 
compounds. Thus, a group of Chinese researchers used 
squaraic acid chloride (67) in the synthesis of a series of 
alkyl 2-chloropyrimido[1,2-a]benzimidazole-3-carboxylates 
68a–g (Scheme 21).64 Remarkably, the study revealed that 
the reaction proceeds in various alcohols with the 
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This is confirmed by a study on the synthesis of 1,4-di-
methylpyrimido[1,2-a]benzimidazol-2(1H)-one (81), obtained 
by alkylation of pyrimidobenzimidazole 80 with dimethyl 
sulfate hydrate. In addition, the study provides detailed data 
on the properties of compound 81 revealed by X-ray 
structural analysis and quantum-chemical calculations 
(Scheme 24).67 
Scheme 22 
formation of the corresponding alkyl derivatives of 
pyrimidobenzimidazole carboxylates 68a–g, while in aprotic 
solvents (MeCN, THF, and DMF) the reaction mixture 
underwent resinification and individual reaction products 
could not be isolated due to the extreme instability of the 
squaraic acid derivative and the resulting intermediates. 
Keto esters and their derivatives are another important 
synthon in the series of 1,3-dicarbonyl  compounds for 
the construction of the pyrimidine ring. A method was 
developed for the synthesis of a wide range of pyrimido-
[1,2-a]benzimidazol-4-one derivatives 70a–h by cyclo-
condensation of β-keto esters 69 with 2-amino-
benzimidazole (1a) under the conditions of microwave 
activation.65 Of note is the high yields of products (74–
94%) as well as a short reaction time (3 min). In addition, a 
number of derivatives 71a–h containing a methylene- 
coumarin fragment in their molecules were synthesized on 
the basis of the obtained compounds (Scheme 22). 
In addition to the above approach, a group of authors in 
2015 published data on the condensation of various β-keto 
esters 72–75 with 2-amino-5,6-dimethylaminobenz-
imidazole (1b).66 The reactions were carried out by heating 
under reflux in EtOH, and in all cases good yields of the 
corresponding pyrimido[1,2-a]benzimidazoles 76–79 were 
attained (Scheme 23). The only drawback of this method is 
the long reaction time (8–24 h) in comparison with the 
conditions shown in Scheme 22. It should be noted that in 
both cases the formation of pyrimido[1,2-a]benzimidazol-
4-ones was noted; however, the formation of pyrimido-
[1,2-a]benzimidazol-2-ones can also be assumed. 
Scheme 23 
Scheme 24 
The use of ethyl acetoacetate derivatives 74b and 82 for 
the construction of the pyrimidobenzimidazole structure 
was demonstrated. Methods for the synthesis of halo-
genated 2-methylpyrimido[1,2-a]benzimidazol-4(10H)-ones 
83a,b, 84a,b, 85a, 86a,b, 87a were developed, the 
alkylation of their sodium salts 88a, 89a, 90a,b, 91a was 
studied, and the structure of the regioisomeric methylation 
products 92a, 93a, 94a,b, 95a, 96a, 97a, 98a,b, 99a was 
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established (Scheme 25).68 Regioisomeric pairs 92a/96a, 
93a/97a, 94a/98a, 94b/98b, 95a/99a were resolved using 
column chromatography. 
An example of the use of dibasic acid esters described 
by a team of Italian researchers is the multistep synthesis of 
novel 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]-
benzimidazol-4-ones 103a–o using malonic ester 75b.69 
The synthetic strategy included the initial alkylation of 
2-aminobenzimidazole (1a), condensation of the obtained 
products 100a–o with malonic ether 75b effected by 
EtONa, chlorodeoxygenation of the obtained 
pyrimidobenzimidazole-2,4-diones 101a–o, and nucleophilic 
ipso substitution of the halogen in compounds 102a–o by 
the piperazine moiety (Scheme 26). 
Derivatives of keto esters are also widely used in the 
synthesis of the pyrimidine moiety. A publication from 
2011 presents the results of the synthesis of new 
3-benzimidazolylpyrimidobenzimidazoles 106 under 
conditions of phase-transfer catalysis by benzyltriethyl-
ammonium chloride (BTEAC). Initially, the condensation 
of benzimidazole 1a with hydrazones of ethyl acetoacetate 
104 was carried out, as a result of which pyrimido-
benzimidazoles 105 were obtained. The subsequent 
reaction of azo derivatives 105 with carbene obtained in 
Scheme 25 
Scheme 26 
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situ from 3-chloro-3-methylbut-1-yne in a basic medium 
completes the transformation (Scheme 27).70 
Derivatives of bifunctional compounds containing an 
active methylene group which are widely used in the 
synthesis of pyrimidobenzimidazole derivatives deserve 
special attention. A study of Polish researchers was 
devoted to the reaction of 2-diethoxyphosphoryl-3-methoxy-
acrylate (107) with aza-heterocycles, including 2-amino-
benzimidazole (1a). It was shown that carrying out the 
reaction in xylene at 140°С for 30 h leads to the formation 
of the final pyrimidobenzimidazolone 108.71 The relatively 
mild conditions under which pyrimidinone 108 is formed, 
in comparison with other considered heterocycles, clearly 
reflect the higher nucleophilicity of the nitrogen atom of 





The publication of Russian researchers is yet another 
demonstration of the use of α-alkoxymethylene derivatives 
of keto esters (by the example of compounds 109a–c). The 
authors report on the regiodirected synthesis of 
polyfluoroalkyl derivatives of benzimidazopyrimidines  
110–113 a–c, as well as the route of the process depending 
on the fluoroalkyl substituent (Scheme 29).72 
It was found that the nature of the solvent used and the 
size of the fluoroalkyl moiety have a decisive influence on 
the ratio of the resulting compounds. Thus, for 2-ethoxy-
methylidene-4,4,4-trifluoroacetoacetate (109a), cyclization 
via route a is preferable in 1,4-dioxane, whereas in polar 
solvents this cyclization route becomes the only one. 
Tetrafluoroethyl-containing ester 109b shows such 
selectivity only in polar aprotic solvents, while in proton-
donating EtOH and weakly polar 1,4-dioxane, the 
formation of pairs of reaction products 110b/111b and 
112b/113b in about equal total yields is observed which 
indicates that realization of heterocyclization routes a and b 
are equally probable. At the same time, the reaction of 
heptafluoropropyl-substituted ester 109c is characterized 
by a complete lack of selectivity since, regardless of the 
solvent used, cyclization proceeds along both routes (a and b). 
Scheme 29 
A recent study reports the use of 3-ethoxy-2-methyl-
sulfonylacrylonitrile (114) in the synthesis of novel 
aminomethylsulfonylpyrimidines. In particular, the reaction 
of compounds 1а and 114 in 1,4-dioxane in the presence of 
Et3N yielded 4-amino-3-(methylsulfonyl)pyrimido[1,2-a]-
benzimidazole (115) (Scheme 30).73 
An example of the creation of nitro derivatives of 
pyrimidobenzimidazoles is the synthesis of 3-nitropyrimido-
[1,2-a]benzimidazol-4-ones 117a–c and a detailed study of 
the alkylation of these derivatives described in a 
publication from 2017. Based on the studies carried out, it 
was found that alkylation proceeds at the N-1 and N-10 
atoms with the formation of two series of regioisomeric 
products 118–121 a–c and 122–125 a–c, respectively 
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(Scheme 31). In addition, the ratio of regioisomers was 
determined, which depends on the nature of the used alkyl 
iodide. In the case of alkylation with methyl, ethyl, or 
n-propyl iodide, the ratio of the products of 1- and 
10-substitution is 1:0.7. In the reaction with isopropyl 
iodide, this ratio is 1:0.5.74 
By changing the catalyst and solvent, a team of Indian 
researchers obtained pyrimidobenzimidazole derivatives 
133a–k via the reaction of Morita–Baylis–Hillman acetates 
132a–k and 2-aminobenzimidazole (1a) (Scheme 33).78 
Another approach for the construction of polycyclic 
derivatives of pyrimidobenzimidazoles is the synthesis of 
hexacyclic derivative 135 was demonstrated in a 
publication from 2014.79 Compound 135 was obtained by 
annulation of 2-aminobenzimidazole (1a) and benzo-
thiazolopyrimidine 134 (Scheme 34). The authors of this 
paper paid much attention to the study of the mechanism 
and regioselectivity of the process. 
As mentioned earlier, reactions catalyzed by microwave 
irradiation are quite common and relevant in condensation 
Scheme 31 
Wong and colleagues presented a series of publications 
on the synthesis of pyrimidobenzimidazoles 127, 129, 131 
via the reaction of 2-aminobenzimidazole (1а) with Baylis–
Hillman acetates, alcohols, and amines 126, 128, 130, 
respectively.75–77 The methods presented by the authors 




















































1 a R = H, d R = F, e R = Cl
118–125 a R = H, b R = F, c R = Cl
118, 122 R1 = Me; 119, 123 R1 = Et;
















133 a R1 = R2 = R3 = H, Y = CH, X = C (82%)
b R1 = Br, R2 = R3 = H, Y = CH, X = C (80%)
c R1 = Me, R2 = R3 = H, Y = CH, X = C (77%)
d R1 = H, R2 = Br, R3 = F, Y = CH, X = C (68%)
e R1 = Br, R2 = H, R3 = Cl, Y = CH, X = C (70%)
f R1 = H, R2 = H, R3 = ''–'', Y = CH, X = N (70%)
g R1 = H, R2 = Br, R3 = F, Y = N, X = C (67%)
h R1 = OH, R2 = R3 = H, Y = CH, X = C (73%)
i R1 = R2 = H, R3 = F, Y = CH, X = C (60%)
j R1 = R2 = H, R3 = NO2, Y = CH, X = C (51%)
k R1 = H, R2 = CF3, R












Chemistry of Heterocyclic Compounds 2021, 57(4), 383–409 
396 
processes that take place with the elimination of low 
molecular weight compounds (H2O, alcohols, etc.). 
Adhering to this approach, a method was developed for the 
synthesis of pyrimidobenzimidazolone derivatives 137a–g 
based on 2-aminobenzimidazole (1a) and phenylethanones 
136 (Scheme 35).80 
reducing its cost, and making it less environmentally 
harmful due to the use of nontoxic solvents. The latter 
condition is of particular importance for the use of the 
method in the pharmaceutical industry when the 
environmental friendliness of production and the purity of 
the resulting medicinal compound come to the fore as 
criteria for assessing the possibility of its technological 
application. 
Numerous studies81–101 present the synthesis of pyri-
midobenzimidazole derivatives 140 by the three-com-
ponent reaction of 2-aminobenzimidazole (1а), aromatic 
aldehyde derivatives 138, and cyclohexane-1,3-diones 139 
(Scheme 36). Considering the uniformity of the synthetic 
route used in the presented publications, special attention is 




To conclude, the methods for constructing a 
pyrimidobenzimidazole scaffold based on bifunctional 
synthetic equivalents have on the whole been developed in 
sufficient detail, although it cannot be said that they are 
completely exhausted. 
Construction of pyrimidobenzimidazole structure by 
multicomponent reactions 
Among the methods for constructing the azolo-
pyrimidine fragment, multicomponent reactions (MCRs) 
occupy a special place. Due to its simplicity in application 
and wide possibilities for varying all components, MCRs 
open unconventional synthetic routes for the creation of 
new hard-to-access heterocyclic molecular structures. In 
the literature, examples of the use of MCR for the synthesis 
of pyrimidobenzimidazoles are represented by three-
component reactions, the main components of which are 
derivatives of benzimidazoles and aldehydes. The third 
component is labile and is often an active CH component. 
This section of the review is systematized according to the 
variation of the third component of an MCR. 
The development of new catalytic systems and 
determination of their efficiency in MCR was the goal of a 
large number of studies related to the development of MCR 
methodology.81–96 The use of new catalysts and their 
systems allows: simplifying the procedure for obtaining the 
target product, increasing the selectivity of the process, 
Scheme 36 
A team of Iranian scientists describe the use of sulfamic 
acid as a reusable green catalyst under the conditions of 
heating in MeCN for the synthesis of derivatives 140 
(Table 3). It was noted that the use of sulfamic acid as a 
catalyst provides certain advantages, including ease of use, 
ease of isolation, and good product yields, as well as the 
possibility of its reuse.81 
Table 3. Examples of NH2SO3H-catalyzed 
three-component reaction of compounds 1а, 138, and 139 
to obtain compounds 140 
Entry Ar R Reaction time, min Yield, % 
1 Ph Me 15 94 
2 4-ClС6Н4 Me 15 90 
3 4-BrС6Н4 Me 15 90 
4 4-MeOС6Н4 Me 18 90 
5 4-HOС6Н4 Me 20 90 
6 4-O2NС6Н4 Me 18 95 
For the synthesis of derivatives 140, catalytic systems 
were developed in the form of modified Fe3O4 
nanoparticles containing:82–87 
– silica with terminal sulfo groups;82 
– L-proline fragments;83 
– chitosan structures;84 
– starch with n-butylsulfo group;85 





















137 a R1 = R2 = H (81%); b R1 = Me, R2 = H (72%)
c R1 = H, R2 = Me (86%); d R1 = OMe, R2 = H (70%)
e R1 = H, R2 = OMe (92%); f R1 = Br, R2 = H (93%)
g R1 = H, R2 = Br (88%)
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4-ones 149a–m from 2-aminobenzimidazole (1а), aromatic 
aldehydes 147, and thio derivative 148 (as an active CH 
component) was investigated.100 The process was carried 
out under the conditions of heating the components in an 
AcOH medium at 50°C for 8–10 h (Scheme 37). 
Another interesting example was demonstrated in the 
work of Egyptian researchers by a method of obtaining 
poly(tetrahydrobenzimidazo[2,1-b]quinazolin-1-one) 152 
by multicomponent condensation of 2-aminobenzimidazole 
(1a), polyaldehyde 150, and dimedone (151) in DMF 
catalyzed by ZnO nanoparticles under the conditions of 
microwave radiation (Scheme 38).101 
A innovative method for constructing benzimidazo-
quinazolinone structures 154a–h is presented in a 
publication from 2016.102 The difference between this 
approach and the above is that benzyl halide derivatives 
153 which are oxidized with trimethylamine N-oxide are 
used instead of an aromatic aldehyde (Scheme 39). 
A large number of studies103–120 devoted to the synthesis 
of pyrimidobenzimidazoles 157 using MCR of keto esters 
and their various derivatives 155 as well as malononitrile 
(156) are presented in general in Scheme 40. 
A series of publications103–106 was devoted to the study 
of MCRs of malononitrile (156), 2-aminobenzimidazole 
(1а), and aromatic aldehydes 138. Alum103 was used as a 
condensation catalyst; at the same time PTSC was 
successfully used,104 and Mexican researchers carried out 
the synthesis by heating the components under reflux in 
H2O.
105 In addition, the successful use of polyvinyl-
pyrrolidonium perchlorate as a highly efficient catalyst in 
Figure 3. Ionic liquids used in MCR synthesis of pyrimido-
[1,2-a]benzimidazoles 140. 
Among the advantages of these catalysts are high 
efficiency (yields of derivatives 140 of over 90%), 
reusability, and compliance with the principles of green 
chemistry. In addition, one of the main features of these 
catalytic systems is their magnetic activity, which makes it 
possible to separate the catalyst from the reaction mixture 
using an external magnet. 
Another group of catalysts used for MCR shown in 
Scheme 36 are ionic liquids 141–145 (Fig. 3).88–92 Among 
the advantages of the considered catalysts are their 
cheapness, ease of preparation, and high stability. In 
addition, the research emphasizes the possibility of reuse of 
catalysts without losing their activity. In addition, it should 
be noted that the significant reduction in the reaction time 
and high yields of derivatives 140 make these catalysts 
attractive for many other studies in the field of synthesis of 
various nitrogenous heterocycles. While not proven, they 
are assumed to be of a general nature. 
A series of studies was devoted to the use of acid 
catalysts in the synthesis of derivatives 140.93–96 Consi-
dered among the catalysts are polyvinylpyrrolidonium 
hydrogen sulfate,93 (CH2)4(DABCO–SO3H)2Cl4 nano-
particles,94 PTSA,95 and AcOH.96 Among the advantages of 
using this series of catalysts, high yields of reaction 
products, ease of use, and environmental friendliness of the 
process are given. 
The main tasks for optimizing the conditions for 
carrying out any synthetic process, along with increasing 
the yield of the target product, include the reduction of the 
reaction time. Microwave radiation is used to intensify 
many reactions in organic chemistry. From this point of 
view, the implementation of the process as shown in 
Scheme 36 under microwave irradiation conditions without 
solvent and catalysts,97 as well as under the conditions of 
catalysis by Sc(OTf)3
98 is of great synthetic importance. 
In 2016, the synthesis of derivatives 140 using a deep 
eutectic solvent 146, which is a mixture of choline chloride 
and glycerol was described (Fig. 4).99 Along with high 
yields, short reaction times, and mild reaction conditions, 
the main advantage of the investigated solvent is its 
biodegradability. 






















Figure 4. The structure of solvent 146. 
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The selectivity of the process of the MCR of 
2-aminobenzimidazole (1a), aromatic aldehydes 158a–f, 
ethyl cyanoacetate (155a), and malononitrile (156) 
(Scheme 41) was studied.108,109 In the above studies, 
compounds exhibiting basic properties were investigated as 
condensation catalysts: NaOAc, Et3N, and MgO. It has 
been shown that their use provides high yields and product 
purity. In addition, it is noted that in this case the reaction 
proceeds selectively with the formation of products 161a,b 
and 162a–f. The regioselectivity of the process is explained 
by the formation of the Knoevenagel condensation 
products 159 and 160, the further reaction of which with 
aminobenzimidazole 1a is due to the increased 
electrophilicity of the methylene and ethoxycarbonyl 
fragments. As a result, the reaction products 161' and 162' 
are not preferred in the given process conditions. 
Another example of a MCR using malononitrile (156) 
and aromatic aldehydes 163a–l was described in 2018.110 It 
is noteworthy that the developed approach uses a 
nanostructured ionic liquid, a salt of imidazole and 
trinitromethane [HIMI]C(NO2)3 (Scheme 42). As noted by 












































a Ar = Ph, b Ar = 4-MeC6H4,
c Ar = 4-MeOC6H4, d Ar = 4-ClC6H4,


























154 a Ar = 3-NCC6H4 (94%), b Ar = 4-ClC6H4 (92%),
c Ar = Ph (90%), d Ar = 4-BrC6H4 (92%),
e Ar = 3,5-(MeO)2C6H4 (88%), f Ar = 2,4,6-(MeO)3C6H4 (88%),










































































the preparation of 1,4-dihydropyrimido[1,2-a]benzimida-
zole-3-carbonitrile derivatives 157 (R1 = NH2, R
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reaction time, increases the yields of pyrimidobenz-
imidazoles 164a–l, and also allows the process to be 
carried out in accordance with the principles of green 
chemistry.  
Keto esters and diketones are important substrates 
for the construction of the pyrimidobenzimidazole 
scaffold.111–120 In these studies, the present synthetic 
strategy for the preparation of pyrimidobenzimidazoles 
corresponds to the approach shown in Scheme 36. The 
relevance of the research lies in demonstrating the broad 
capabilities of various catalysts and their systems in MCRs. 
Thus, the synthesis of 1,4-dihydropyrimido[1,2-a]benz-
imidazole-3-carboxylates 169a–y using ionic liquids 167, 
168 as catalysts and in the absence of solvents (Scheme 43) 
was presented.111,112 It was noted that when using these 
catalysts condensation proceeded smoothly with a wide 
range of substrates 165, 166, and the products were 
obtained in good or excellent yields (Table 4). In addition, 
the low cost of catalysts and the possibility of their reuse, 
as well as the ease of product isolation, are the main 
advantages of the developed methods. 
In a number of studies on the preparation of pyrimido-
[1,2-a]benzimidazoles, the catalytic activity of some 
natural compounds, such as L-proline,113 thiamine 
hydrochloride,114 and citric acid was investigated.115 Along 
with all the advantages of organocatalysts, the described 
procedures are carried out in aqueous media, which 
expands the field of application of the MCR. At the same 
time, the efficiency of catalysts, a wide range of substrates 
used, and mild reaction conditions significantly expand the 









































R R1 R2 Yield, % 
169a 4-FC6H4 Et Ph 95 
169b 4-ClC6H4 Et Ph 92 
169c 3-ClC6H4 Et Ph 91 
169d Et t-Bu Me 90 
169e Pr t-Bu Me 92 
169f 2-Thienyl t-Bu Me 89 
169g 4-O2NC6H4 t-Bu Me 94 
169h 4-MeC6H4 t-Bu Me 95 
169i 3-ClC6H4 t-Bu Me 91 
169j 4-NCC6H4 Et Me 93 
169k 4-MeOC6H4 Et Me 92 
169l 1,3-Benzodioxol-5-yl Et Me 89 
169m 4-EtOC6H4 Et Me 93 
169n 2,5-Me2C6H3 Et Me 91 
169o 2,4-F2C6H3 Et Me 90 
169p 2-F-5-BrC6H3 Et Me 89 
169q C6H11 Et Me 92 
169r 2-F-4-BrC6H3 Et Me 89 
169s 2-F-4-BrC6H3 Me Me 91 
169t C6H11 Me Me 90 
169u 2,4-F2C6H3 Me Me 91 
169v 4-NCC6H4 Me Me 92 
169w 1,3-Benzodioxol-5-yl Me Me 88 
169x 2-F-5-BrC6H3 Me Me 90 
169y 2,5-Me2C6H3 Me Me 91 
A simple and effective method for the synthesis of 
pyrimido[1,2-a]benzimidazole derivatives 169m, 172a–m 
(Table 5) using N,N'-dichlorobis(2,4,6-trichlorophenyl)urea 
(CC-2) (171), aromatic aldehydes 170, and keto esters 74a,b 
was demonstrated by Indian researchers (Scheme 44).116 
The main advantage of the method is that reagent 171 is 
converted during the reaction into insoluble 1,3-bis(2,4,6-
trichlorophenyl)urea which can easily be separated by 
simple filtration and converted back to CC-2 by treatment 
with AcOH/Cl2/NaOH. 
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In 2014, Indian researchers studied the effect of zinc 
perchlorate (Zn(ClO4)2·6H2O) on the MCR of aldehydes 
173, ethyl acetoacetate (74b), and 2-aminobenzimidazole 
(1a) in the synthesis of a number of pyrimido[1,2-a]-
benzimidazole derivatives 172j, 174a–i (Scheme 45).117 
The authors note high yields of the reaction products; 
however, in the case of using aldehydes containing an OH 
group in position 2 or 4 of the phenyl ring, a decrease in the 
yields of the target product is observed. 
carrying out the reaction without a solvent. In addition to 
the above approach, a team of authors from Iran reported 
the use of N,N,N',N'-tetrabromobenzene-1,3-disulfonamide 
(TBBDA) (175) and poly(N-bromo-N-ethylbenzene-1,3- 
disulfonamide) (PBBS) (176) as MCR catalysts (Fig. 5).119 
These catalysts also allow solvent-free reactions. 
A method was developed for the synthesis of new 
adenosine receptor A2B antagonists. Among the synthesized 
structures, the most significant in terms of their activity 
were pyrimido[1,2-a]benzimidazole derivatives 178a–h 
which were synthesized via a MCR of aldehydes 177, keto 
esters 74b,c, and 2-aminobenzimidazole (1a).120 
Optimization of the synthesis showed that that the 
synergistic use of chloroacetic acid (as a catalyst) and 
microwave irradiation led to a significant increase in the 
yields of compounds 178a–h (Scheme 46). 
* No information is provided in the publication as to which isomer of 











169m 4-EtOC6H4 Et 78 172g 4-НONC6H4 Et 71 
172a 4-MeOC6H4 Et 82 172h 4-MeOC6H4 Et 75 
172b 4-EtC6H4 Et 76 172i 3-НOC6H4 Et 66 
172c 4-Me2CH Et 72 172j 4-Me2NC6H4 Et 65 
172d 4-FC6H4 Et 68 172k 4-F3CC6H4 Et 58 
172e 4-O2NC6H4 Et 70 172l 3,4,5-(MeО)3C6H2 Me 55 
172f 3-O2NC6H4 Me 68 172m Indolyl* Me 55 
Table 5. The yields of of 1,4-dihydropyrimido- 
[1,2-a]benzimidazole-3-carboxylates 169m, 172a–m 
Scheme 44 
Scheme 45 
Figure 5. The structures of catalysts 175 and 176. 
Scheme 46 
Another catalytic system used in the synthesis of 
pyrimido[1,2-a]benzimidazoles is H3PO4 supported on 
Al2O3.
118 Among the advantages of this catalyst are the 

























178 a R = Et, X = O, Y = CH (55%); b R = i-Pr, X = O, Y = CH (61%)
c R = Et, X = CH, Y = O (72%); d R = i-Pr, X = O, Y = CH (71%)
e R = Et, X = S, Y = CH (68%); f R = i-Pr, X = S, Y = CH (66%)
g R = Et, X = CH, Y = S (68%); h R = i-Pr, X = CH, Y = S (67%)
74b (R = Et)
c (R = i-Pr)
Among other substrates used in MCRs, derivatives of 
terminal alkynes are of interest.121–123 Thus, the 
regioselective synthesis of pyrimido[1,2-a]benzimidazoles 
181a–aa by the reaction of 2-aminobenzimidazoles 1, 
aldehydes 179, and alkynes 180 is described. The reaction 
is carried out in MeCN under reflux using a copper and 
silver salt system as a catalyst (Scheme 47).121 
A particular example of the use of alkyne derivatives in 
the synthesis of pyrimido[1,2-a]benzimidazoles is a work 
by Chinese researchers.124,125 The authors have developed 
an approach to the synthesis of disubstituted pyrimido- 
[1,2-a]benzimidazoles 184a–o using the MCR of 
benzimidazole 1a, aldehydes 182, and alkynecarboxylic acids 
183 in the presence of a catalytic amount of CuI and K2CO3 
(Scheme 48). 
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 Scheme 47 
Scheme 48 
Chemistry of Heterocyclic Compounds 2021, 57(4), 383–409 
402 
Chinese researchers have demonstrated the possibility of 
using 1-benzyl-3-methylimidazolium tetrafluoroborate 
([bmim]BF4) as an effective catalyst in the three-
component condensation of aminobenzimidazole 1а, 
1,4-naphthoquinone (187), and aromatic aldehydes 188 for 
the synthesis of derivatives of pyrimido[1,2-a]benz-
imidazoles 189a–o (Scheme 50).127 When selecting the 
conditions, it was found that carrying out the reaction in the 
absence of a solvent at 100°C allows one to achieve better 
yields (Table 6). 
In another example of constructing the pyrimido[1,2-a]-
benzimidazole structure under the MCR conditions, 
2-aminobenzimidazole (1а), aromatic aldehydes 195, and 
(E)-N-methyl-1-(methylsulfanyl)-2-nitroethylenamine (196) 
were used as the reaction components.129,130 The process 
was carried out by melting the components in the presence 
of a novel ionic liquid based on imidazolium dication 
grafted onto a polyethylene glycol methacrylate support 
PEGMA-g-TEGBDIM,129 or by heating in EtOH under 
reflux in the presence of PTSA as a catalyst (Scheme 52).130 
A characteristic of the described approach lies in the 
possibility of accessing nitro derivatives of pyrimido-
Scheme 49 
Compound R Reaction time, min Yield, % 
189a 4-ClC6H4 11 83 
189b 3-FC6H4 11 83 
189c 3-HOC6H4 12 85 
189d 4-FC6H4 12 86 
189e 3-ClC6H4 11 86 
189f 3-ClC6H4 12 86 
189g 2,3-Cl2C6H3 12 85 
189h 4-BrC6H4 12 85 
189i 2-BrC6H4 12 84 
189j 2-ClC6H4 14 82 
189k 3,4-(MeO)2C6H3 11 86 
189l 2-MeOC6H4 12 84 
189m 3,4-Cl2C6H3 14 83 
189n 2,3-(MeO)2C6H3 13 85 
189o 2,4-Cl2C6H3 14 86 
Scheme 50 In 2014, multicomponent condensation between 
acetophenones 184, aminobenzimidazole 1a, and aromatic 
aldehydes 185 was carried out by Hassaneen and 
Farghaly.126 The reaction was carried out in H2O in the 
presence of H-ferrierite zeolite for the short period of time 
of 8–15 min. The developed method made it possible to 
obtain a new series of pyrimido[1,2-a]benzimidazoles 186a–f 
in good yields (Scheme 49). 
Table 6. The yields of pyrimido[1,2-a]benzimidazole derivatives 
89a–o 
Scheme 51 
As mentioned earlier, microwave irradiation in most 
cases has a positive effect on the course of a MCR. Thus, in 
one of the studies, microwave irradiation was used for the 
three-component condensation of benzimidazole 1a, ketone 
derivatives 190, and aldehydes 191, 193 to obtain pyrimido-
[1,2-a]benzimidazole derivatives (Scheme 51). The yields 
of compounds 192a–g ranged from 60 to 93%, the yields of 
compounds 194a–g – from 67 to 92%.128 
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* Activity is expressed as the diameter of the zone of inhibition  
(mean ± standard deviation), mm. 
** NA – no activity. 













7a 17.3 ± 0.63 NA** 17.4 ± 0.58 NA 
7b 19.3 ± 1.2 NA 19.2 ± 0.58 NA 
Ampicillin 23.8 ± 1.2 27.4 ± 0.72 NA NA 
Ciprofloxacin NA NA 25.3 ± 1.2 23.4 ± 0.63 
benzimidazoles 197a–v. It is known that nitroazolo-
pyrimidines and their derivatives possess useful biological 
activity.33,131–135 In addition, the presence of such an 
important structural fragment as the nitro group seems to 
be promising from the point of view of further 
transformations, for example, in the creation of polycyclic 
purine-like structures.136 
Biological activity of pyrimidobenzimidazole 
derivatives 
Some examples of biologically active derivatives of 
pyrimidobenzimidazoles are presented below. Compounds 
7a,b were tested for antimicrobial and antifungal activity 
in vitro against two fungal species, namely Aspergillus 
niger and Syncephalastrum racemosum, and four bacterial 
species: Gram-positive Staphylococcus aureus, Enterococcus 
faecalis and Gram-negative Klebsiella pneumoniae and 
Pseudomonas aeruginosa (Table 7). Compounds 7a,b did not 
show antifungal activity. The antimicrobial activity of these 
compounds was found to be lower than that of the reference 
drugs.  
Pyrimidobenzimidazoles 9a–d were tested for 
antibacterial activity against Gram-positive bacteria 
Bacillus subtilis and Staphylococcus aureus and Gram-
negative bacteria Escherichia coli and Pseudomonas 
aeruginosa (Table 8).39 
As seen in Table 8, compound 9d showed the best 
activity against both Gram-positive and Gram-negative 
bacteria: its values of the zones of inhibition are close to 
those of the reference drugs. 
The study of the biological activity of pyrimido-
benzimidazole structures 21, 23 was presented in a study 
from 2017.45 In vitro antiproliferative activity of these 
compounds against the MCF-7 cell line was investigated. 
While compound 23 showed good activity, benzoic acid 
derivative 21 was found to be inactive (IC50 values 18.2 
and 41 μg/ml, respectively). Antimicrobial activity of 
compounds 21 and 23 against Gram-positive bacteria 
Bacillus subtilis, Streptococcus pneumoniae and Gram-
negative bacteria Pseudomonas aeruginos and Escherichia 
coli was investigated. Compared with the reference drug 
amphotericin B, compounds 21 and 23 exhibited moderate 
activity (Table 9). 
In vitro studies of a wide range of pyrimido[1,2-a]-
benzimidazoles 55a–k for antibacterial activity against 
Staphylococcus aureus, Bacillus subtilis, Vibrio 
parahaemolyticus, and Proteus mirabilis were presented 
using chloramphenicol as a standard antibacterial agent 
with a broad spectrum of action. Based on the results of the 
in vitro studies, compounds 55a,c were selected as 
candidates for further biological tests (Table 10).57 
The synthesized galeterone derivatives containing a 
pyrimidobenzimidazole fragment were tested for anti-
proliferative activity. The values of the maximum inhibition 













9a 16.7 ± 0.3 16.4 ± 0.3 10.4 ± 0.3 8.1 ± 0.3 
9b 18.5 ± 0.3 13.7 ± 0.3 9.4 ± 0.3 6.8 ± 0.3 
9c 18.5 ± 0.5 20.4 ± 0.6 15.5 ± 0.3 18.4 ± 0.2 
9d 24.1 ± 0.3 20.2 ± 0.4 19.0 ± 0.3 20.3 ± 0.3 
Penicillin G 26.2 ± 0.3 24.6 ± 0.3 – – 
Streptomycin – – 26.7 ± 0.5 20.6 ± 0.8 
* Activity is expressed as the diameter of the zone of inhibition  
(mean ± standard deviation), mm. 
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Table 10. In vitro antibacterial activity of compounds 55a,c 

















18.7 ± 0.25 
16.2 ± 0.44 
25.4 ± 0.1 
16.2 ± 0.58 
13.9 ± 0.19 
28.7 ± 0.2 
– 
– 
19.7 ± 0.2 
17.3 ± 0.44 
15.8 ± 0.19 
23.7 ± 0.1 
* Activity is expressed as the diameter of the zone of inhibition (mean ± 
standard deviation), mm. 
of cell proliferation (GI50) of compounds 60a–c, 60'c, 61a–c, 
and 60''a lie in the middle micromolar range (Table 11).60 
Pyrimidobenzimidazole derivatives 70, 71 a–h65 showed 
antibacterial activity with a MIC of 2 μg/ml against Gram-
positive bacteria and 1 μg/ml against Gram-negative 
bacteria. Compounds 70, 71 a–h showed antibacterial 
activity superior to ciprofloxacin against Enterococcus 
faecalis with a MIC of 0.2 to 0.8 μg/ml. 
The antifungal activity of these compounds was evaluated in 
comparison with flucanozole (MIC 16 μg/ml for Candida 
albicans and 8 μg/ml for Aspergillus niger, Aspergillus 
fumigatus, Aspergillus flavus, Fusarium oxysporum, and 
Penicillium chrysogenum). Compounds 70f,g were highly 











55a 95.5 55.5 10.0 110.5 
55c 73.5 32.5 8.5 85.5 































































Table 11. Antiproliferative activity of compounds 60, 60', 61, 





C4-2* VcaP* PC3** 
60a 7.2 ± 1.5 22.5 ± 2.3 >50 >50 
60b 40.0 ± 10.0 36.5 ± 0.2 >50 >50 
60c 29.9 ± 3.1 24.4 ± 1.6 >50 >50 
60'c >50 >50 >50 >50 
60d 26.3 ± 3.7 >50 >50 >50 
60e 12.4 ± 5.1 12.7 ± 0.5 20.7 ± 0.9 7.8 ± 0.7 
60f 1.4 ± 0.72 1.7 ± 0.4 2.0 ± 0.3 >100 
60g >50 >50 >50 >50 
60h 4.3 ± 3.7 1.1 ± 0.1 >50 >50 
61a 5.4 ± 0.3 18.0 ± 2.1 >50 >50 
61b 7.4 ± 0.6 >50 n. t.*4 >50 
61c >50 >50 n. t.*4 >50 
60''a 6.2 ± 0.7 11.9 ± 0.1 20.3 ± 1.6 29.5 ± 7.8 
Galeterone*** 37.8 ± 0.7 >40 (74.3%) >40 (57.2%) 37.7 ± 1.7 
Enzalutamide >40 (84.0%) >40 (91.5%) >40 (61.2%) >40 (74.0%) 
* Androgen receptor positive cell lines. 
** Androgen receptor negative cell line. 
*** Data in parentheses represent viability in the presence of 40 μM 
concentration of compound. 
*4 Not tested. 
with a MIC of 0.2 μg/ml. Compounds 70b,d,e,g,h showed 
excellent activity against Fusarium oxysporum with a MIC of 
0.2 μg/ml. 
Cytotoxicity, expressed as percentage (%) of dead cells 
at a concentration of a test compound of 100 μg/ml, was 
assessed in comparison with 5-fluorouracil (88% dead 
cells) on Dalton's Lymphoma Ascites cells. Compounds 
70b,d,f,g and 71b,d,e,g were highly active (>70% dead 
cells) against these cells. 
Compounds 76–79 were tested for antimicrobial and 
antifungal activity.66 Compound 77 exhibited the broadest 
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spectrum of antimicrobial activity. All compounds 
exhibited antifungal activity. The best indicators for 
compounds 76 and 77 were against Aspergillus flavus; for 
compound 79 – against Fusarium oxysporum, and for 
compound 78 – against Aspergillus ochraceus. 
Pyrimidobenzimidazoles 129 were evaluated for pesti-
cidal activity.75 Derivatives 129a–d were the most active 
against Plutella xylostella at a concentration of 100 mg/ml 
with a lethality of 70–90%. At a concentration of 
compounds 129a–d of 500 mg/ml, the lethality against 
Tetranychus cinnabarinus was 100% (Table 12). 
HEK-293 (hA2B) cells for compounds 178a–h was studied 
in vitro (Table 16).120 Along with tricyclic compounds, 
monocyclic 3,4-dihydropyridin-2(1H)-ones, bicyclic pyrrolo-
pyrimidinones, and furopyrimidinediones were also consi-
dered. Pyrimidobenzimidazoles, in particular compounds 
178a–d,g,h, showed the best affinity for the hA2B receptor 
(Ki ≤ 25 nM). The selective A1 receptor antagonist 1,3-di-
propyl-8-cyclopentylxanthine (DPCPX) and the selective 






Tetranychus cinnabarinus* Plutella xylostella** 
129a 4-ClC6H4 100 80 
129b 4-FC6H4 100 70 
129c 4-O2NC6H4 100 90 
129d 2-Fur 100 80 
* Concentration of compounds 129a–d 500 mg/ml. 
** Concentration of compounds 129a–d 100 mg/ml. 
Table 12. Toxicity of compounds 129a–d against Tetranychus 
cinnabarinus and Plutella хylostella 
Table 13. The profile of acetylcholinesterase inhibition in vitro 
by compounds 133a–e,g–j 
Compound Inhibition 
(at 208 nМ), %* IC50, nМ 
133a 53 70.78 ± 10.01 
133b 70 52.64 ± 1.07 
133c 62 91.8 ± 3.6 
133d 76 46.86 ± 1.16 
133e 74 42.52 ± 5.17 
133g 69 71.48 ± 5.04 
133h 61 67.32 ± 4.94 
133i 67 52.58 ± 15.65 
133j 65 68.4 ± 7.94 
Tacrine 66 551.58 ± 19.17 
Galantamine – 360 ± 101 
For structures 133a–e,g–j, an in vitro study of inhibition 
of acetylcholinesterase was carried out. The results in 
comparison with known inhibitors are presented 
(Table 13).78 Compounds 133d,e showed the best result 
among other compounds 133 and significantly higher 
inhibitory efficacy at lower IC50 values in comparison with 
drugs tacrine and galantamine. 
Compound 135 was studied against Gram-positive, Gram-
negative bacteria, as well as against the fungi Geotrichum 
candidum and Aspergillus fumigatus79 (Table 14). Compound 
135 exhibited both antimicrobial and antifungal activity, but 
showed MIC values much higher than those of the reference 
drugs. 
Pyrimidobenzimidazole derivatives 137a–g were 
evaluated in vitro for antioxidant activity80 (Table 15). The 
evaluation was carried out in two directions: a) interaction 
with DPPH (1,1-diphenyl-2-picrylhydrazyl) and b) inhi-
bition of sodium linoleate peroxidation by 2,2'-azobis- 
(2-amidinopropane) dihydrochloride (AAPH) and soy 
lipoxygenase (LOX). Such well-known antioxidant agents 
as nordihydroguaiaretic acid (NDGA), ionol (BHT), and 
trolox were selected as objects of comparison. According 
to the results of the study, the most effective compound 
with antioxidant activity against peroxidation was 
compound 137a, while derivatives 137d,e showed 
moderate activity. 
The affinity for human adenosine receptors A1, A2A, 













135 100 100 100 12.5 
Streptomycin 3.125 3.125 6.25 6.25 
Chloramphenicol 6.25 6.25 6.25 6.25 
 Fungi  
 Geotrichum candidum Aspergillus fumigatus 
135 25 50 
Triflucan 3.125 3.125 
Table 14. Antimicrobial and antifungal activity (MIC, μg/ml) 
of compound 135 









20 min 60 min 0.01 mM 0.1 mM 0.01 mM 0.1 mM 
137a 5.03 2 1 11 100 49 100 
137b 6.03 – – 8 80 – 40 
137c 6.03 4 5 35 84 – 19 
137d 4.87 3 2 3 100 – – 
137e 6.45 2 2 33 97 – – 
137f 6.75 3 2 9 78 51 61 
137g 6.56 – 3 51 88 – 12 
NDGA 3.92 81 83 – – 40 84 
BHT 5.43 31 60 – – – – 
Trolox 3.09 – – – 63 – – 
Table 15. Antioxidant activity of compounds 137a–g assessed 
by the interaction with DPPH and in vitro inhibition of sodium 
linoleate peroxidation by APPH and LOX, and the lipophilicity 
index (C logP) 
* Data are expressed as Ki or percent inhibition of specific binding at 
1 μM concentration of compound (n = 2) for those compounds that did not 
completely displace radioligand binding. 
** [3H]DPCPX and [3H]ZM241385 were used as radioligands in binding 
assays. 
Table 16. Affinity of pyrimidobenzimidazoles 178a–h 
for human adenosine receptors 
Compound 
Ki, nМ, or inhibition, %* 
hA1 hA2A hA2B hA3 
178a 5% 14% 12.03 ± 0.7 1% 
178b 20% 25% 3.49 ± 0.2 2% 
178c 7% 11% 20.60 ± 1.1 1% 
178d 12% 22% 11.40 ± 0.5 2% 
178e 8% 16% 484.6 ± 3 1% 
178f 1% 17% 371.2 ± 5 3% 
178g 3% 10% 29.71 ± 1.2 2% 
178h 11% 3% 29.34 ± 1.1 21% 
[3H]
DPCPX** 
2.20 ± 0.2 157 ± 2.9 73.24 ± 1.4 1722 ± 11 
[3H]
ZM241385** 











a R = Et, X = O, Y = CH
b R = i-Pr, X = O, Y = CH
c R = Et, X = CH, Y = O
d R = i-Pr, X = O, Y = CH
e R = Et, X = S, Y = CH
f R = i-Pr, X = S, Y = CH
g R = Et, X = CH, Y = S
h R = i-Pr, X = CH, Y = S
A team of scientists from India synthesized pyrimido-
benzimidazole derivatives 192, 194 a–g and studied in 
vitro their antimicrobial, anti-tuberculosis (Table 17), and 
antimalarial activity (Table 18).128 Most of the compounds 
tested for antimicrobial activity showed excellent potential 
in relation to Salmonella typhi, Streptococcus pneumoniae, 
Bacillus subtilis, and Clostridium tetani compared to the 
antibiotic ampicillin. Compounds 192c,g and 194f,g (MIC 
100 μg/ml) exhibited activity greater than ampicillin (MIC 
250 μg/ml) and equal to ciprofloxacin (MIC 100 μg/ml). 
According to in vitro antifungal screening data, 
compound 194b exhibited activity against Candida 
albicans (MIC 100 μg/l), equivalent to nystatin, while 
compound 192f turned out to be also highly active (MIC 
250 μg/ml), surpassing the known drug griseofulvin (MIC 
500 μg/ml). The activity of compounds 192b,d,e and 
194b,e,f against Trichophyton rubrum was equal to 
nystatin and griseofulvin (MIC 500 μg/ml). 
Table 17. In vitro anti-tuberculosis activity of 
compounds 192, 194 a–g against Mycobacterium tuberculosis 
H37Rv at a concentration of 250 μg/ml 
Com- 
pound 
Inhibition, % Compound Inhibition, % 
192a 61 194b 94 
192b 91 194c 62 
192c 78 194d 85 
192d 64 194e 90 
192e 83 194f 74 
192f 65 194g 73 
192g 61 Rifampicin 98 
194a 70 Isoniazid 99 
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Compound IC50, μg/ml Compound IC50, μg/ml 
192a 0.051 194b 0.041 
192b 0.030 194c 1.50 
192c 1.84 194d 1.45 
192d 1.52 194e 0.054 
192e 1.19 194f 0.83 
192f 1,75 194g 0.092 
192g 0.079 Chloroquine 0.020 
194a 1.45 Quinine 0.268 
Table 18. In vitro antimalarial activity 
of compounds 192, 194 a–g against Plasmodium falciparum 
When screening for anti-tuberculosis activity, it was 
found that compounds 192b and 194b,e have the highest 
efficacy with an inhibition rate of 91, 94, and 90%, 
respectively. The rest of the compounds showed weak 
inhibition of the growth of Mycobacterium tuberculosis. 
Compounds 192a,g and 194b,e,g showed the best 
activity against the Plasmodium falciparum strain with IC50 
values in the range of 0.030–0.092 μg/ml (Table 18). The 
authors identify compounds 192b and 194b,e as promising 
antimicrobial, anti-tuberculosis, and antimalarial agents. 
 
This review systematizes the results on the creation of 
pyrimidobenzimidazole structures over the past 10 years. 
The obtained compounds demonstrate a wide spectrum of 
biological activity, comparable to the activity of existing 
drugs on the market. Thus, pyrimidobenzimidazoles are 
promising objects in the search for means of combating 
diseases on a global scale and deserve the most serious 
attention in further studies of their structural modifications. 
 
The reported study was funded the RFBR, project No. 
19-33-90161. 
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